Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tango Therapeutics, Inc. (TNGX) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology company. Tango Therapeutics files a range of documents with the U.S. Securities and Exchange Commission that describe its financial condition, capital markets activities, and key corporate events, complementing its focus on discovering and developing precision cancer medicines using synthetic lethality.
Through Forms 8-K, Tango Therapeutics reports material events such as equity financings, at-the-market offering programs, and private placements, including underwriting agreements for registered offerings of common stock and pre-funded warrants, and securities purchase agreements for PIPE transactions. These filings often explain the intended use of proceeds, which the company has stated includes advancing its pipeline and supporting working capital and general corporate purposes, as well as expectations for its cash runway.
Other 8-K filings furnish press releases that summarize quarterly financial results and provide business highlights, including updates on clinical trials for vopimetostat (TNG462), TNG456, and TNG260. Filings also document corporate governance developments, such as leadership transitions, board appointments, and executive departures. Registration statements and prospectus supplements referenced in these filings outline the structure and terms of Tango Therapeutics’ capital raising activities.
On Stock Titan, users can review Tango Therapeutics’ SEC filings alongside AI-powered summaries that help explain the significance of each document. This includes quick insights into quarterly earnings releases (often furnished on Form 8-K), material financing agreements, at-the-market sales agreements, and other key disclosures. The filings page supports investors who want to understand how Tango Therapeutics funds its clinical-stage oncology programs, manages its capital structure, and reports material corporate events under SEC requirements.
Tango Therapeutics director Lee Sung received new equity awards as part of board compensation. On April 29, 2026, Sung was granted 12,300 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on January 2, 2027, January 2, 2028, and January 2, 2029, contingent on continued board service.
Sung was also granted an option for 5,200 shares of common stock at an exercise price of $22.06 per share. This option vests in 36 substantially equal monthly installments over three years starting January 2, 2026, subject to continued service. Following the grants, Sung holds 22,300 shares of common stock directly and 5,200 stock options, reflecting routine non-employee director compensation rather than open-market trading.
TNGX affiliate submitted a Form 144 notifying an intended sale of 65,460 common shares on 05/01/2026 arising from an exercise of stock options for cash. The filing also reports multiple prior 10b5-1 sales by Adam Crystal totaling reported share lots and proceeds in early 2026.
Tango Therapeutics, Inc. Principal Accounting Officer Jessica Newcomb filed an initial ownership report showing she directly holds 67,321 shares of Common Stock, including 43,666 unvested restricted stock units. She also holds multiple stock options to buy Common Stock at exercise prices between $2.67 and $12.28, expiring between 2032 and 2036, many of which vest over four-year service-based schedules.
Tango Therapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Matthew Gall. The filing identifies him as an officer but, in the provided data, shows no reportable transactions, derivative positions, or other holdings, indicating this is a baseline ownership statement rather than a trading disclosure.
Tango Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026 at 9:00 a.m. Eastern Time. Investors will elect three Class II directors to terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and give an advisory vote on executive pay.
The proxy also highlights clinical progress, including positive 2025 Phase 1/2 monotherapy data for vopimetostat, initiation of combination studies in MTAP-deleted, RAS-mutant cancers, first dosing with brain-penetrant PRMT5 inhibitor TNG456, and a $225 million financing completed in October 2025. There were 144,242,271 common shares outstanding and entitled to vote as of April 7, 2026.
Tango Therapeutics, Inc. President of R&D Crystal Adam exercised stock options to acquire 38,460 shares of common stock at an exercise price of $5.20 per share, then sold 38,460 shares in an open-market transaction at $25.00 per share. Following the sale, she directly holds 112,622 common shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
Tango Therapeutics announced several leadership changes and equity awards to support its late-stage oncology pipeline. The board decided that Daniella Beckman will step down as Chief Financial Officer, principal accounting officer and principal financial officer, effective April 15, 2026.
Effective the same date, Matthew Gall becomes Chief Financial Officer and principal financial officer under an employment agreement that includes an option for 240,000 shares and 40,000 restricted stock units, subject to time-based vesting and continued employment. Jessica Newcomb is appointed principal accounting officer, while a related press release highlights additional senior hires in development operations and corporate strategy to help advance vopimetostat toward potential regulatory approval in pancreatic cancer.
Tango Therapeutics President of R&D Crystal Adam exercised stock options for 27,000 shares of common stock at an exercise price of $5.20 per share and, on the same day, sold 27,000 shares at a weighted-average price of $21.2029 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the sale, Adam directly holds 112,622 shares of Tango Therapeutics common stock.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an option exercise and related stock sale. On March 25, 2026, she exercised stock options to acquire 12,000 shares of common stock at $5.20 per share, then sold 12,000 shares in open‑market transactions at a weighted‑average price of $20.11 per share.
These trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 27, 2025. After the transactions, she held 112,622 shares of common stock directly and 460,500 stock options, indicating the sale represents a relatively small portion of her overall position.